Trulieve Cannabis

CIN rates Trulieve Cannabis Neutral, supported by a 56.3 composite score and modest 2/5 conviction. Fundamentals provide the principal contribution at 78, reflecting exceptional gross-margin, operating-margin, market-capitalization-tier, and cash-runway subscores. Regulatory ranks second at 58, combining a strong jurisdiction posture and clean enforcement record with weak filing cadence. Market contributes only 40 because no institutional quote is available, limiting price-based confirmation. Editorial contributes 30, consistent with no newsroom or brief activity. The pillar mix supports operational quality but lacks the market, disclosure, and coverage breadth required for an Overweight rating.

Revenue declined 3.7% year over year, leaving the growth subscore at 46.3 and separating Trulieve from stronger top-line profiles. That weakness contrasts with a 59.7% gross margin and 12.4% operating margin, which underpin respective subscores of 99.4 and 86.4. EBITDA of approximately $322.6 million demonstrates positive operating cash-generation capacity, while a net loss of roughly $81.1 million keeps the financial condition stretched. A market capitalization near $1.70 billion supports the 89.2 size-tier subscore, but does not offset the bottom-line deficit. Primary regulatory filings show no events during the latest 90-day period versus eight across 180 days, with the latest filing dated July 2, 2026; that pattern drives the low 25 cadence subscore despite no enforcement hits. Licensed fundamentals data, institutional pricing feeds, primary regulatory filings, and CIN newsroom coverage form the stated evidence base.

The clearest catalyst sits within fundamentals, already the strongest pillar. Stable gross margin near 60% and a double-digit operating margin provide meaningful earnings leverage if revenue contraction reverses, enabling a stronger composite without relying on unavailable market pricing or incremental editorial coverage. Continued EBITDA generation supports operations, but the net loss means liquidity and solvency pressure remain relevant under the stretched financial condition. Regulatory improvement requires a more consistent filing cadence, while market confirmation requires restored quote availability. The single most important signal to watch is a return to positive year-over-year revenue growth while current gross-margin strength holds.